Cemiplimab-rwlc

Brand Name

Libtayo18,144-146,#

Pharmacology

Programmed death receptor 1–directed monoclonal antibody

Similars

Nivolumab, pembrolizumab

FDA Indication

Cutaneous squamous cell carcinoma$

Further Reading in Goodman & Gilman’s